August 04, 2017
In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation
Case Number:
2:17-md-02785
Court:
Nature of Suit:
Multi Party Litigation:
Class Action, Multi-district Litigation
Judge:
Firms
- Law Offices of Ursula Taylor
- Groom Law Group
- Foley & Lardner
- Matthew G. Miller PC
- Spencer Fane
- Foulston Siefkin
- Sharp Law LLP
- Parker Waichman
- Holland & Knight
- Siegfried & Jensen
- Spragens Law
- Steven Williams Law
- Barnow & Associates
- Goldman Scarlato
- Robbins Geller
- Squitieri & Fearon
- Wilson Sonsini
- Kramer Levin
- King & Spalding
- Saiber LLC
- Weil Gotshal
- McCune Wright
- Blood Hurst
- Berkowitz Oliver
- Baron & Budd
- Barton & Burrows
- Pallas Partners
- Kaufman & Canoles
- Mehri & Skalet
- Beasley Allen
- Williams & Connolly
- Robbins Russell
- Pritzker Levine
- Gibbs Law Group
- DiCello Levitt
- Gibbons PC
- Lockridge Grindal
- Yarmuth LLP
- Lanier Law Firm
- Keller Rohrback
- Fredrikson & Byron
- Hinkle Law Firm
- Robins Kaplan
- Carella Byrne
- Lathrop GPM
- Burns Charest
- Marion's Inn
- Berman Tabacco
- Sidley Austin
- Clark Hill
- Ali & Lockwood
- Strategic Health Law
- Boies Schiller
- Dollar Burns
- Gibson Dunn
- DLA Piper
- Perkins Coie
- Butler Prather
- Hogan Lovells
- Hagens Berman
- Reed Smith
- Levi & Korsinsky
- Gustafson Gluek
- Goodwin Procter
- Bradford & Wilson
- Horn Aylward
- Joseph Saveri Law Firm
- Bush Seyferth
- Wagstaff & Cartmell
- Shook Hardy
- Lowey Dannenberg
- Lightfoot Franklin
- GM Law PC
- Latham & Watkins
- Mayer Brown
- White & Case
- Willkie Farr
Companies
- Amerigroup Corp.
- Change Healthcare Inc.
- MedImpact Healthcare Systems Inc.
- CVS Health Corp.
- Express Scripts Holding Co.
- Aetna Inc.
- Blue Cross Blue Shield Association
- Coventry Health Care Inc.
- Meridian Medical Technologies Inc.
- The Segal Co. Inc.
- Optum Inc.
- Pfizer Inc.
- Viatris Inc.
- Humana Inc.
- King Pharmaceuticals Inc.
- OptumRx Inc.
- Sanofi
- Centene Corp.
- UnitedHealth Group Inc.
- Teva Pharmaceutical Industries Ltd.
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
March 14, 2022
Judge OKs $264M Deal Ending Mylan EpiPen Price-Hike Suit
A Kansas federal court has preliminarily approved a $264 million deal that would end claims that Mylan colluded with Pfizer Inc. to obstruct generic versions of the EpiPen, the emergency drug used to treat severe allergic reactions, from entering the market.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login